A sensitive and specific radioimmunoassay for LY309887, a potent inhibitor of glycinamide ribonucleotide formyltransferase

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 157-163

  Coleman, Dennis L ^a   Canak, Nedjelko ^a   Place, Gary D ^a   Shih, Chuan ^a   Bowsher, Ronald R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BOVINE SERUM ALBUMIN; COMPOUND 389753; FOLIC ACID; LOMETREXOL; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; N [[[2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D] PYRIMIDIN 6 YL)ETHYL] 2 THIENYL]CARBONYL] GLUTAMIC ACID; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE INHIBITOR; RABBIT ANTISERUM; SUPERPARAMAGNETIC IRON OXIDE; TRACER; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CANCER; CASE REPORT; CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABBIT; RADIOIMMUNOASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYL AND FORMYL TRANSFERASES; IMMUNE SERA; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RABBITS; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; TETRAHYDROFOLATES;

EID: 0031929275     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Habeck, L. L., Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., and Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res., 54: 1021-1026, 1994.
2. Mendelsohn, L. G., Shih, C., Schultz, R. M., and Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest. New Drugs, 14: 287-294, 1996.
3. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, R. G. A new antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF), is a potent inhibitor of de novo purine synthesis. J. Biol. Chem., 264: 328-333, 1989.
4. Nelson, R., Butler, F., Dugan, W., Jr., Davisland, C., Stone, M., and Dyke, R. Phase I clinical trial of LY264616 (DDATHF). Proc. Am. Soc. Clin. Oncol., 9: 76, 1990.
5. Young, C., Currie, V., Baltzer, L., Trochanowski, B., Eton, O., Dyke, R., and Bowsher, R. Phase I and clinical pharmacologic study of LY264618, 5,10-dideazatetrahydrofolate. Proc. Am. Assoc. Cancer Res., 31: 177, 1990.
6. Laohavinij, S., Wedge, S., Lind, M., Bailey, N., Humphreys, A., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Robson, L., Gumbrell, L., Taylor, G., Thomas, H., Boddy, A., Newell, D., and Calvert, A. H. A Phase I clinical study of the antipurine antifolate lumetrexol (DDATHF) given with oral folic acid. Invest. New Drugs, 14: 325-335, 1996.
7. Ray, M. S., Muggia, F. M., Leichman, C. G., Grunberg, M. G., Nelson, R. L., Dyke, R. W., and Moran, R. G. Phase I study of (6R)-5,10-dideazatetrahydro-folate: a folate antimetabolite inhibitory to de novo prine synthesis. J. Natl. Cancer Inst., 85: 1154-1159, 1993.
8. Worzalla, J. F., Rutherford, P. G., Self, T. D., Seymour, P. D., Theobald, K. S., Mendelsohn, L. G., Gossett, L. S., Shih, C., Schultz, R. M., and Grindey, G. B. In vivo antitumor activity of LY309887, a new antifolate inhibitor of glycinamide ribonucleotide formyl transferase. Proc. Am. Assoc. Cancer Res., 36: 378, 1995.
9. Fong, K-L., Ho, D. H. W., Benjamin, R. S., Yang, F., Sickler, J., Brown, N. S., and Bodey, G. P. A radioimmunoassay for 5-methyltetrahydrohomofolate. J. Pharmacol. Exp. Ther., 278: 344-347, 1981.
10. Taber, L. D., O'Brien, P., Bowsher, R. R., and Sportsman, J. R. Competitive particle concentration fluorescence immunoassay for measuring 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) in serum. Clin. Chem., 37: 254-260, 1991.
11. Bohuon, C., Duprey, F., and Boudene, C. Radioimmunoassay of methotrexate in biological fluids. Clin. Chim. Acta, 57: 263-267, 1974.
12. Raso, V., and Schreiber, R. A rapid and specific radioimmunoassay for methotrexate. Cancer Res., 35: 1407-1410, 1975.
13. Paxton, J. W., and Rowell, F. J. A rapid, sensitive and specific radioimmunoassay for methotrexate. Clin. Chim. Acta, 80: 563-572, 1977.
14. Aherne, G. W., Piall, E. M., and Marks, V. Development and application of a radioimmunoassay for methotrexate. Br. J. Cancer, 36: 608-617, 1977.
15. Albertioni, F., Rask, C., Eksborg, S., Poulsen, J. H., Pettersson, B., Beck, O., Schroeder, H., and Peterson, C. Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin. Chem., 42: 39-44, 1996.
16. Erlanger, B. F., Borek, F., Beiser, M., and Lieberman, S. Steroid-protein conjugates. I. Preparation and characterization of bovine serum albumin with testosterone and with cortisone. J. Biol. Chem., 228: 713-727, 1957.
17. Erlanger, B. F., Borek, F., Beiser, M., and Lieberman, S. Steroid-protein conjugates. II. Preparation and characterization of bovine serum albumin with progesterone, deoxycorticosterone, and estrone. J. Biol. Chem., 234: 1090-1094, 1959.
18. Bowsher, R. R., Compton, J. A., Kirkwood, J. A., Place, G. D., Jones, C. D., Mabry, T. E., Hyslop, D L., Hatcher, B. L., and DeSante, K. A. Sensitive and specific radioimmunoassay for fialuridine: initial assessment of pharmacokinetics after single oral doses to healthy volunteers. Antimicrob. Agents Chemother., 38: 2134-2142, 1994.
19. Parker, C. W. Radiolabeling of proteins. In: M. P. Deutscher (ed.), Guide to Protein Purification: Methods in Enzymology, Vol. 182, pp. 721-726. San Diego, CA: Academic Press, Inc., 1990.
20. Dudley, R. A., Edwards, P., Ekins, R. P., Finney, D. J., McKenzie, I. G. M., Raab, G. M., Rodbard, D., and Rodgers, R. P. C. Guidelines for immunoassay data processing. Clin. Chem., 31: 1264-1271, 1985.
21. Buick, A. R., Doig, M. V., Jeal, S. C., Land, G. S., and McDowall, R. D. Method validation in the bioanalytical laboratory. J. Pharm. Biomed. Anal., 8: 629-637, 1990.
22. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A., Layloff, T., Viswanathan, C. T., Cook, C. E., McDowall, R. D., Pittman, K. A., and Spector, S. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci., 81: 309-312, 1992.
23. Langone, J. J. Radioimmunoassay of methotrexate, leucovorin, and 5-methyltetrahydrofolate. In: J. J. Langone and H. Van Vunakis (eds.), Methods in Enzymology, Vol. 84, pp. 409-422. New York: Academic Press, Inc., 1982.
24. Kato, Y., Paterson, A., and Langone, J. J. Monoclonal antibodies to the chemotherapeutic agent methotrexate: production, properties, and comparison with polyclonal antibodies. J. Immunol. Methods, 67: 321-324, 1984.
25. Balthasar, J. P., and Fung, H-L. High-affinity rabbit antibodies directed against methotrexate: production, purification, characterization, and pharmacokinetics in the rat. J. Pharm. Sci., 84: 2-6, 1995.
26. 2+ controlled antigen antibody systems. Adv. Exp. Med. Biol., 48: 161-183, 1974.
27. Callahan, H. J., and Maurer, P. H. The occurrence of antibodies in rabbit anti-pneumococcus antisera directed against calcium dependent and independent determinants. Immunol. Commun., 4: 537-552, 1975.
28. Hendel, B. Radioimmunoassay for pteroylglutamic acid. Clin. Chem., 27: 701-703, 1981.
29. Paxton, J. W., Rowell, F. J., and Cree, G. M. Comparison of three radioligands, selenium-75, iodine-125, and tritium, in the radioimmunoassay of methotrexate. Clin. Chem., 24: 1534-1538, 1978.
30. Bore, P., Rahmani, R., Cano, J-P., Just, S., and Barbet, J. Radioimmunoassays of 7-hydroxymethotrexate and methotrexate. Clin. Chim. Acta, 141: 135-149, 1984.
31. Wedge, S. R., Laohavinij, S., Taylor, G. A., Boddy, A., Calvert, A. H., and Newell, D. R. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin. Cancer Res., 1: 1479-1486, 1995.
32. Seideman, P., Beck, O., Eksborg, S., and Wennberg, M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br. J. Clin. Pharmacol., 35: 409-412, 1993.
33. Bannwarth, B., Pehourcq, F., Schaeverbeke, T., and Dehais, J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet., 30: 194-210, 1996.